Cannabis Bioscience International Holdings, Inc. (CBIH) Cash & Equivalents (2022 - 2026)

Cannabis Bioscience International Holdings has reported Cash & Equivalents for 5 years, with the latest figure at $90.0 in Q1 2026.

• Quarterly Cash & Equivalents fell 83.58% year-over-year to $90.0 in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $90.0 (down 83.58% YoY) and the FY2025 annual result came in at $12952.0, up 1615.5% from the prior year.
• Cash & Equivalents retreated to $90.0 in Q1 2026 per CBIH's latest filing, from $132.0 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $25655.0 in Q1 2023 and troughed at $90.0 in Q1 2026.
• A 5-year average of $5800.4 and a median of $881.5 in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents tumbled 98.6% in 2023, then surged 1615.5% in 2025.
• Over 5 years, Cash & Equivalents stood at $24089.0 in 2022, then plunged by 98.6% to $337.0 in 2023, then soared by 197.33% to $1002.0 in 2024, then sank by 86.83% to $132.0 in 2025, then sank by 31.82% to $90.0 in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $90.0, $132.0, and $223.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.